Michael Schlichting

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier et al. · European Journal of Cancer · 2012 · 593 citations

Medicine, Oncology, Pharmacology +12

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian et al. · Journal of Clinical Oncology · 2017 · 582 citations

Medicine, Oncology, Pharmacology +17

Association of <i>KRAS</i> G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

Sabine Tejpar, Ilhan Celik, Michael Schlichting et al. · Journal of Clinical Oncology · 2012 · 353 citations

Medicine, Oncology, Pharmacology +16